MULTINATIONAL, MULTICENTRIC, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY, IN PARALLEL GROUPS, TO EVALUATE THE EFFICACY OF ZOLEDRONIC ACID ADMINSTRATED BY INTRAVENOUS VIA IN THE PREVENTION OF OSTEOPOROTIC FRACTURES AFTER A HIP FRACTURE.
Not Applicable
- Conditions
- -S729S729
- Registration Number
- PER-061-02
- Lead Sponsor
- OVARTIS BIOSCIENSES PERU S.A.,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Male or female ages 50 years or older
Must have a recent hip fracture repair in the past 90 days
Must be able to walk with or without assistive device (for example, using a walker) prior to the hip fracture.
Exclusion Criteria
Current bisphosphonate users such as aredia (pamidronate), didronel (etidronate), fosamax (alendronate), actonel (residronate), skelid (tiludronate) Other protocol-defined inclusion/exclusion criteria may apply.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method